Effects of Xal-Ease on Patient Compliance With Xalatan

NCT00573638

Last updated date
Study Location
Medical College of Georgia Health Inc
Augusta, Georgia, 30912, United States
Contact
706-721-1150

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

706-721-1150

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 40 to 80 years old

- Diagnosis warranting treatment with Xalatan eye drops.

- ambulatory and well functioning

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- non-ambulatory


- less than 40 or greater than 80 years old


- Not using Xalatan eye drops

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

GlaucomaEffect of Age on Latanoprost 0.005% in Patients With Glaucoma
NCT00224289
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
GlaucomaDoes Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?
NCT00799994
  1. Philadelphia, Pennsylvania
ALL GENDERS
0+
years
MULTIPLE SITES
GlaucomaHow Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
NCT00798694
  1. Philadelphia, Pennsylvania
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Effects of Xal-Ease on Patient Compliance With Xalatan
Official Title  ICMJE The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops
Brief Summary The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Glaucoma
Intervention  ICMJE Device: Xal-Ease device to be used with Xalatan eye drops
This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: December 13, 2007)
50
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2009
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 40 to 80 years old
  • Diagnosis warranting treatment with Xalatan eye drops.
  • ambulatory and well functioning

Exclusion Criteria:

  • non-ambulatory
  • less than 40 or greater than 80 years old
  • Not using Xalatan eye drops
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00573638
Other Study ID Numbers  ICMJE 05-02-266
Guarantor or CPI # 002533552
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Michelle Christiano, Medical College of Georgia
Study Sponsor  ICMJE Augusta University
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Christian D. Nilson, MDAugusta University
PRS Account Augusta University
Verification Date August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP